KDR and melanoma: Recent studies have shown that rapamycin (also called sirolimus), an mTOR inhibitor, blocks the mTOR signaling pathway leading to suppression of angiogenesis and lymphangiogenesis in melanoma, and downregulates the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3.